Efficacy and safety of fruquintinib plus sintilimab in third-line treatment of metastatic colorectal cancer: A single-center experience

Figure 1 Flowchart of patient selection. SD: Stable disease; PD: Progression disease; CR: Complete response.

Figure 2 Combined Positive Score. A: Patient 1, Combined Positive Score (CPS) = 1; B: Patient 2, CPS = 5; C: Patient 3, CPS = 5; D: Patient 4, CPS = 0; E: Patient 5, CPS = 0; F: Patient 6, CPS = 6. CPS: Combined Positive Score.

Figure 3 Imaging. A: Patient 1, baseline; B: Patient 1, after 3 cycles; C: Patient 2, baseline; D: Patient 2, after 4 cycles; E: Patient 3, baseline; F: Patient 3, after 3 cycles; G: Patient 4, baseline; H: Patient 4, after 6 cycles; I: Patient 5, baseline; J: Patient 5, after 12 cycles; K: Patient 6, baseline; L: Patient 6, after 2 cycles. Orange arrows indicate the main lesions. Baseline refers to imaging at initiation of fruquintinib combined with sintilimab.

Figure 4 Survival analysis. A: Median progression-free survival of third-line treatment; B: Median overall survival of third-line treatment. PFS: Progression-free survival; OS: Overall survival; CI: Confidence interval.

Figure 5 Palmar-plantar erythrodysesthesia syndrome in patient 1. A: Right hand; B: Left hand; C: Right foot; D: Left foot.